Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients with Metabolic Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Behavioral, Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

VLCKD has showed to be an impactful diet on several metabolism aspects and has proven to be useful for preventing and treating diabetes mellitus type 2, overweight, chronic inflammation and fatty liver. For this reason, the aim of this pilot study is to examinate the potential effect of a VLCKD on a group of patients that contemporarily have DM2, obesity and Non alcholic fatty liver disease (NAFLD), comparing the results with an ipocaloric diet based on Mediterranean Principles and Italian LARN (SINU 2014). This study will consider several interrelated outcomes such as anthropometric data, hematochemical and hormonal parameters, questionnaires, stool microbiota and omics, blood microvescicles, urine tests, instrumental tests (DXA, BIVA, ecographies), biopses and functional tests. 40 subjects will be evaluated and divided in two groups of 20 (VLCKD) and 20 (MedDiet).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 65
Healthy Volunteers: f
View:

• Age 25-65

• BMI 30-40 mg/m2

• NAFLD

• DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, basal insulin) and HbA1c \> 7 and \< 10 %.

Locations
Other Locations
Italy
: Italy Pediatric Endocrine Service of AOU Maggiore della Carità of Novara; SCDU of Pediatrics, Department of Health Sciences, University of Eastern Piedmont
RECRUITING
Novara
Contact Information
Primary
Flavia Prdoam, Prof. MD
flavia.prodam@med.uniupo.it
+39 0321 660 693
Time Frame
Start Date: 2022-11-07
Estimated Completion Date: 2025-12
Participants
Target number of participants: 40
Treatments
Experimental: VLCKD
20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~* Age 25-65~* BMI 30-40 mg/m2~* NAFLD~* DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c \> 7 and \< 10 %.
Active_comparator: Hypocaloric Mediterranean Diet
20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~* Age 25-65~* BMI 30-40 mg/m2~* NAFLD~* DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c \> 7 and \< 10 %.
Sponsors
Collaborators: Laboratoire THERASCIENCE
Leads: Azienda Ospedaliero Universitaria Maggiore della Carita

This content was sourced from clinicaltrials.gov